Brook Baker, a law professor at Northeastern University in Boston, said he doubts the pharmaceutical industry will pull back much on its investments in India based on the decision. The country will still grant 20 year patents on new, innovative drugs and a growing middle class with chronic diseases will provide many business opportunities, he said.
“I think there is plenty of incentives for them to come to India,” Baker said in a telephone interview. “They always cry doomsday and say no one will invest in India because it isn’t an investor-friendly country. But companies will invest in India because they can make money there.”